A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor
Phase of Trial: Phase I/II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs AZD 5363 (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FAKTION
- 21 Aug 2017 Planned End Date changed from 1 Aug 2016 to 1 Oct 2019.
- 21 Aug 2017 Planned primary completion date changed from 1 May 2016 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated